Live
AgilentAgilent Technologies Advances Chromatography Innovations for Pharma and Biotech in 2026 - AD HOC NEWSLonza NewsLonza Group AG Stock Faces Pressure Amid Biopharma Sector Slowdown and Capacity Utilization Concerns - AD HOC NEWSCellThe BMP Inhibitor Coco Reactivates Breast Cancer Cells at Lung Metastatic SitesIlluminaSwiss Life Asset Management Ltd Purchases 67,772 Shares of Illumina, Inc. $ILMN - MarketBeatThermo FisherSarasin & Partners LLP Decreases Holdings in Thermo Fisher Scientific Inc. $TMO - MarketBeatLonza NewsLonza Group AG stock faces pressure amid biotech slowdown as of March 2026 - AD HOC NEWSLonza NewsNature of Things: Lonza, antibodies and Solano County’s biotech future - Daily Republic10x Genomics BlogHow ARK’s TXG Selloff and Cautious 2026 Outlook Will Impact 10x Genomics (TXG) Investors - simplywall.stCellHyperinnervation inhibits organ-level regeneration in mammalian skinCellDeciphering mechanical determinants of morphological evolutionCellAn activated wheat CC<sub>G10</sub>-NLR immune receptor forms an octameric resistosomeCellThe E3-ome gene-centric compendium reveals the human E3 ligase landscape
BioWorld Jan 16, 2026

Latigo Biotherapeutics identifies Nav1.8 blockers

Latigo Biotherapeutics identifies Nav1.8 blockers

Original
Body unavailable. Use the original source.

Directory

59 All